Oligohydramnios
Conditions
Keywords
Oligohydramnios, Hydrotherapy, Pregnancy
Brief summary
OBJECTIVE: To assess the efficacy of subtotal immersion therapy as an option to improve maternal intravascular volume thereby improving both maternal and fetal hemodynamic status with reversal of oligohydramnios. This will be measured utilizing the Amniotic Fluid Volume (AFV) as the primary outcome. Secondary outcomes will be measured using Fetal Doppler Studies, Maternal vital signs (Blood Pressure, Pulse Pressure, Weight, Pulse) and input/output. HYPOTHESIS: Oligohydramnios, secondary to depleted maternal intravascular volume, can be reversed by improving feto- and uteroplacental perfusion with subtotal immersion therapy.
Detailed description
BACKGROUND: The volume of amniotic fluid is relevant clinically as derangements that decrease volume result in a condition known as oligohydramnios, which can have profound implications on perinatal outcome. The incidence of oligohydramnios is 2.3%1,2,3 and measurements of amniotic fluid volume (AFV) has become a standard in fetal surveillance in the evaluation of high risk pregnancies as oligohydramnios is associated with intrauterine growth restriction, respiratory distress syndrome, post-maturity syndrome, and chronic fetal hypoxia. Oligohydramnios may also play a role in fetal malpresentation, umbilical cord compression, meconium staining, and increased operative delivery.3,4, 5,6 Oligohydramnios is commonly defined as an AFV of 5 cm or less. An AFV of 8 cm represents the fifth percentile of normal AFV values.7 It has been observed that delivery in the setting of isolated oligohydramnios, irrespective of an otherwise uncomplicated term gestation free of maternal disease, has become routine thereby increasing maternal morbidity particularly in context of operative delivery or failed inductions. 3 In order to understand oligohydramnios it is first important to understand intrauterine water and progressive changes that occur with normal human gestation. At term, it is reported that total water accumulation is approximately 3.5L, with 2400 mL in the fetus, 400 mL in the placenta, and 700 mL in the amniotic fluid.8 In 1989, Brace and colleagues determined amniotic fluid volume (AFV) as a function of gestational age. They reported an increase in mean values from 30mL at 10weeks to 190mL at 16wks to 780mL at 32-35wks after which time AFV decreases, especially in post-term pregnancies. It is important to realize; however, that the pattern of volume fluctuation as a function of gestational age may vary considerably between individuals. As a general rule AFV increases at a rate of 10ml/wk at the beginning of the fetal period, this rate of expansion increases to 50-60ml/wk from 19 to 25wks at which time a gradual decrease begins to take place until the rate of exchange is zero around 34wks. The pathophysiology of amniotic fluid regulation is not entirely understood at this current date, but it is safe to state that AFV is the integrated sums of the inflow and outflow tracts of the amniotic space.8 Because fluid can move with relative ease between fetal and maternal blood across the placenta and amniotic membranes it stands to reason that a maternal hypovolemia secondary to dehydration would lead to the development of oligohydramnios. This was indeed shown to be the case by Sherer, et al in their 1990 publication. Furthermore, both oral and serum hydration as a way to increase maternal volume have been shown to be effective treatments for oligohydramnios.3,11-16
Interventions
* Maternal BP (sitting) * Pulse Pressure * Pulse * Urine Specific Gravity BID * Fetal Heart Rate * Maternal Body Weight US Procedures * AC/EFW * Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge}) * Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge}) * AFI (Baseline, day 3, 7 {or Discharge}) ALL ITEMS ABOVE MUST BE COMPLETED BEFORE: * 1 Liter Water PO over 2 hours * 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation * Strict I/O's * Vital signs
* Maternal BP (sitting) * Pulse Pressure * Pulse * Urine Specific Gravity BID * Fetal Heart Rate * Maternal Body Weight US Procedures * AC/EFW * Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy * Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy * AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy ALL ITEMS ABOVE MUST BE COMPLETED BEFORE: * 1 Liter Water PO over 2 hours * 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation * Strict I/O's * Vital signs * HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy
Sponsors
Study design
Eligibility
Inclusion criteria
* Maternal Age \>18 years * Oligohydramnios: diagnosed by sonography (defined AFV\<8cm) * Singleton Pregnancy * Intact membranes * Gestational age 24 - 36 weeks
Exclusion criteria
* Indication for urgent delivery (severe PET, HELLP syndrome, persistent fetal hypoxemia \[non-reassuring fetal heart rate pattern\]) * Ruptured amniotic membranes; PPROM, PROM, SROM * Fever (\>38C) * Multiple gestation * \>37 week gestation * Lethal Fetal anomalies and/or demise * Maternal Cardiovascular disease * Maternal Renal disease * Maternal Pulmonary disease (other than asthma) * Patients using prostaglandin inhibitors, NSAIDs3,15 (within 1 week of enrollment, other than baby asprin) * Non-English speaking * Vaginal Infections and/or active skin lesions * Placenta Previa and/or Unexplained Vaginal Bleeding * BMI \> 45
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1. Primary: Number of Participants With Reversal of Oligohydramnios Using AFV Measures | days 3, and 7 or discharge | Subjects amniotic fluid index via ultrasound on days 3, 5 and 7 of study participation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic Status | admission, days 3, 5, 7/discharge and delivery | Secondary: \- Changes in maternal hemodynamic status by mobilizing extravascular fluid |
Countries
United States
Participant flow
Recruitment details
Recruitment began April 8, 2012 and ended April 2014. Recruitment took place at Banner Good Samaritan hospital based on Banner IRB approval.
Pre-assignment details
There were no pre-assignment events.
Participants by arm
| Arm | Count |
|---|---|
| IV/Oral Hydration and Bedrest IV/Oral Hydration and Bedrest:
* Maternal BP (sitting)
* Pulse Pressure
* Pulse
* Urine Specific Gravity BID
* Fetal Heart Rate
* Maternal Body Weight US Procedures
* AC/EFW
* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
* AFI (Baseline, day 3, 7 {or Discharge})
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:
* 1 Liter Water PO over 2 hours
* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation
* Strict I/O's
* Vital signs | 2 |
| Hydrotherapy Group • HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS
o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy
Hydrotherapy:
* Maternal BP (sitting)
* Pulse Pressure
* Pulse
* Urine Specific Gravity BID
* Fetal Heart Rate
* Maternal Body Weight US Procedures
* AC/EFW
* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
o 1 hour +/- 30 minutes after submersion therapy
* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:
* 1 Liter Water PO over 2 hours
* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation
* Strict I/O's
* Vital signs | 2 |
| Total | 4 |
Baseline characteristics
| Characteristic | IV/Oral Hydration and Bedrest | Hydrotherapy Group | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 2 Participants | 4 Participants |
| Age, Continuous | 31.5 years | 23 years | 27.25 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 2 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | 1 Participants | 2 Participants |
| Region of Enrollment United States | 2 Participants | 2 Participants | 4 Participants |
| Sex: Female, Male Female | 2 Participants | 2 Participants | 4 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 2 | 0 / 2 |
| serious Total, serious adverse events | 0 / 2 | 0 / 2 |
Outcome results
1. Primary: Number of Participants With Reversal of Oligohydramnios Using AFV Measures
Subjects amniotic fluid index via ultrasound on days 3, 5 and 7 of study participation.
Time frame: days 3, and 7 or discharge
Population: no formal analysis done on the 4 enrolled patients, study halted due to poor enrollment. Data cannot be reported due to participant privacy.
Metabolic Status
Secondary: \- Changes in maternal hemodynamic status by mobilizing extravascular fluid
Time frame: admission, days 3, 5, 7/discharge and delivery
Population: No analysis done as study halted for poor enrollment only 4 subjects enrolled total. Detailed Data cannot be reported due to participant privacy.